Skip to main content
. 2021 Feb 4;20:410–421. doi: 10.1016/j.omto.2021.02.001

Figure 4.

Figure 4

The immunophenotypes in the IMvigor210 cohort reflected the different responses to anti-PD-L1 immunotherapy

(A) Reappearing three immunophenotypes in IMvigor210 cohort. (B) The distribution of the best confirmed overall response to anti-PD-L1 treatment in the three immunophenotypes. (C) The distribution of complete response and progressive disease in the three immunophenotypes. Non-IM, non-immune class; IM-Act, immune-activated subgroup; IM-Exh, immune-exhausted subgroup.